The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial
Abstract
In Brief Objective: Evaluation of the use of testosterone therapy for hypoactive sexual desire disorder (HSDD) after oophorectomy has mostly involved women treated with oral estrogen preparations. We investigated the efficacy and safety of a testosterone patch in surgically menopausal women receiving concurrent transdermal estrogen. Design: Women with HSDD after oophorectomy, for whom this was a concern, who were using transdermal estrogen, were recruited to a 24-week, randomized, double-blind, placebo-controlled trial in Europe and Australia. Patients were randomly allocated to placebo (n = 40) or testosterone 300 μg/day (n = 37) treatment. Primary endpoints were changes in sexual desire measured by the sexual desire domain of the Profile of Female Sexual Function and the frequency of satisfying sexual activity at 24 weeks. Results: Sixty-one women (79%) completed the trial. All subjects who received at least one application of study medication were included in analysis. The testosterone-treated group experienced a significantly greater change from baseline in the domain sexual desire score compared with placebo (change from baseline, 16.43 versus 5.98; P = 0.02). The domain scores for arousal, orgasm, decreased sexual concerns, responsiveness, and self-image as well as decreased distress were also significantly greater with testosterone therapy than placebo. The frequency of satisfactory sexual events increased but was not statistically different between treatment groups (P = 0.06) Adverse events occurred with similar frequency in both groups, and no serious risks of therapy were observed Conclusions: In this study, transdermal testosterone therapy via a skin patch improved sexual desire and other sexual function domains. It was well tolerated in these oophorectomized women with HSDD receiving concomitant transdermal estrogen. Published studies of testosterone therapy for surgically menopausal women have mostly involved concurrent oral estrogen therapy. In this trial, oophorectomized women with low sexual desire using transdermal estradiol therapy were treated with transdermal testosterone therapy or placebo. Testosterone therapy significantly improved sexual desire and other sexual function domains versus placebo and was well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among adult women, endogenous testosterone does not show significant correlations with sexual behavior (Roney and Simmons, 2013), but exogenous testosterone treatment in women has been found to increase sexual desire, sexual activity, and sexual self-image (Buster et al., 2005, Davis et al., 2006, Shifren et al., 2006).”
From Becoming a sexual being: The “elephant in the room” of adolescent brain development (2017) · cites this paper as Davis et al., 2006
Citations
Cites
Sexual Dysfunction in the United States: Prevalence and Predictors
Laumann, E. O., Paik, A., & Rosen, R. C. (1999) · JAMA · doi:10.1001/jama.281.6.537 · Cited by 5,119
Assessment of quality of life in clinical trials of cardiovascular therapies
WENGER, N. K., Mattson, M. E., Furberg, C. D., & Elinson, J. (1984) · The American Journal of Cardiology · doi:10.1016/s0002-9149(84)80232-5 · Cited by 986
Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.
Shifren, J. L., Braunstein, G. D., Simon, J. A., Casson, P. R., Buster, J. E., Redmond, G. P., Burki, R. E., Ginsburg, E. S., Rosen, R. C., Leiblum, S. R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009073431002 · Cited by 954
(1984) · Medical Entomology and Zoology · Cited by 741
Sherwin, B. B., Gelfand, M. M., & Brender, W. (1985) · Psychosomatic Medicine · doi:10.1097/00006842-198507000-00004 · Cited by 547
Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality
Davis, S. R., McCloud, P., Strauss, B. J., & Burger, H. (1995) · Maturitas · doi:10.1016/0378-5122(94)00898-h · Cited by 534
Self-citationTestosterone patch for low sexual desire in surgically menopausal women: a randomized trial
Buster, J. E., Kingsberg, S. A., Aguirre, O., Brown, C., Breaux, J. G., Buch, A., Rodenberg, C. A., Wekselman, K., & Casson, P. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000158103.27672.0d · Cited by 433
Self-citationRosen, R. C., Taylor, J. F., Leiblum, S. R., & Bachmann, G. A. (1993) · Journal of Sex & Marital Therapy · doi:10.1080/00926239308404902 · Cited by 395
The role of androgen in the maintenance of sexual functioning in oophorectomized women.
Sherwin, B. B., & Gelfand, M. M. (1987) · Psychosomatic Medicine · doi:10.1097/00006842-198707000-00009 · Cited by 394 · cited 1×
“5 [31, 58] 29 42 [30, 69] 300 Kg/day 33 50 [40, 85] 29 42 [36, 63] 25 54 [41, 63] Total dihydrotestosterone [6-31 ng/dL] Placebo 31 8 [5, 12] 29 7 [5, 11] 25 9 [6, 14] 300 Kg/day 31 6 [4, 8] 27 19 [14, 27] 22 17.”
Cited by
Sorted by citations
ESHRE Guideline: management of women with premature ovarian insufficiency
The ESHRE Guideline Group on POI, Webber, L. J., Davies, M. C., Anderson, R. A., Bartlett, J., Braat, D. D. M., Cartwright, B., Cífková, R., Keizer‐Schrama, S. D. M., Hogervorst, E., et al. (2016) · Human Reproduction · doi:10.1093/humrep/dew027 · Cited by 1,603
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176
Nelson, L. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0808697 · Cited by 1,189
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N. F., Braunstein, G. D., Burger, H., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 687
Self-citationHormone replacement therapy in young women with primary ovarian insufficiency and early menopause
Sullivan, S. D., Sarrel, P. M., & Nelson, L. M. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.09.046 · Cited by 519
Metadata
- Authors
- Davis, S. R., van der Mooren, M. J., van Lunsen, R. H. W., Lopes, P., Ribot, J., Rees, M., Moufarege, A., Rodenberg, C., Buch, A., & Purdie, D. W.
- Affiliations
- Jean Hailes (AU)
- Hôpital Rangueil (FR)
- John Radcliffe Hospital (GB)
- Procter & Gamble (United Kingdom) (GB)
- Procter & Gamble (United States) (US)
- Corresponding author
- Davis, Susan R.
- ORCID
- Davis, Susan R.
- Venue
- Menopause
- Published
- 2006-05
- Volume
- 13
- Issue
- 3
- Pages
- 387-396
- ISSN
- 1072-3714 (ISSN-L)
- OpenAlex
- W2799667742
- Cited by
- 250
- References
- 32
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 9 · 2022: 6 · 2021: 10 · 2020: 11 · 2019: 7 · 2018: 13 · 2017: 13 · 2016: 15 · 2015: 7 · 2014: 11 · 2013: 8 · 2012: 18
- FWCI
- 16.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Menopause The Journal of The North American Menopause Society (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, hypoactive sexual desire disorder, oophorectomy, transdermal estradiol, sexual desire, female sexual function, treatment safety
- MeSH terms
- Administration, Cutaneous, Adult, Aged, Double-Blind Method, Estradiol, Female, Humans, Libido, Menopause, Premature, Middle Aged, Ovariectomy, Sexual Dysfunction, Physiological, Testosterone, Treatment Outcome, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
